Biochips Market - Global Forecast To 2030
商品番号 : SMB-91117
| 出版社 | MarketsandMarkets |
| 出版年月 | 2025年11月 |
| ページ数 | 412 |
| 図表数 | 478 |
| 価格タイプ | シングルユーザライセンス |
| 価格 | USD 4,950 |
| 種別 | 英文調査報告書 |
バイオチップ市場は2025年に140.1億米ドル規模となり、年平均成長率8.8%で成長し、2030年には213.6億米ドルに達するとMarketsandMarketsでは予測しています。この成長は、診断、ゲノミクス、そして個別化医療の未来を形作るいくつかの重要な要因によって牽引されています。
MarketsandMarkets（マーケッツアンドマーケッツ）「バイオチップ市場 – 製品とサービス（機器、ソフトウェア）、タイプ（DNAチップ、プロテインチップ、ラボオンチップ）、用途（ハイスループットスクリーニング、IVD、POC）、製造技術（マイクロアレイ、マイクロフルイディクス）、および地域別 – 2030年までの世界予測 – Biochips Market by Products & Services (Instruments, Software), Type (DNA Chips, Protein Chips, Lab-on-a-Chip), Application (High-throughput Screening, IVD, POC), Fabrication Technology (Microarrays, Microfluidics), & Region – Global Forecast to 2030」はバイオチップの世界市場を調査し、主要セグメント別に分析・予測を行っています。
調査対象セグメント
- 製品とサービス
- 消耗品
- 器具
- ソフトウェア＆サービス
- タイプ
- DNAチップ
- ラボオンチップ
- タンパク質チップ（ラボオンチップ）
- 組織アレイ
- セルアレイ
- 作製技術
- マイクロアレイ
- マイクロ流体
- エンドユーザー
- バイオテック企業＆製薬企業
- 病院＆診断センター
- 学術機関＆研究施設
- 医薬品開発受託機関（CRO）
- その他のエンドユーザー
- 地域
- 北米
- 米国
- カナダ
- 欧州
- ドイツ
- 英国
- フランス
- イタリア
- スペイン
- オランダ
- その他の欧州
- アジア太平洋地域
- 中国
- 日本
- インド
- オーストラリア
- 韓国
- タイ
- ニュージーランド
- その他のアジア太平洋地域
- ラテンアメリカ
- ブラジル
- メキシコ
- その他のラテンアメリカ
- 中東＆アフリカ
- GCC諸国
- サウジアラビア王国（KSA）
- アラブ首長国連邦（UAE）
- その他のGCC諸国
- その他の中東＆アフリカ
- GCC諸国
- 北米
この成長の大きな原動力となっているのは、ゲノミクスの進歩と個別化医療への関心の高まりを背景に、精密診断と個別化治療への需要が高まっていることです。医療業界がより個別化された治療計画へと移行するにつれ、遺伝子検査、疾患検出、医薬品開発といった用途におけるバイオチップの採用が急速に拡大しています。
本市場調査は、バイオチップ市場を様々なセグメントにわたって網羅しています。製品・サービス、タイプ、製造技術、エンドユーザー、地域別に、市場規模と成長ポテンシャルを推定することを目的としています。また、主要プレーヤーの詳細な競合分析に加え、企業概要、製品・事業内容に関する主要な考察、最近の動向、主要な市場戦略も提供しています。
本レポートは、既存企業だけでなく、新興企業や小規模企業も市場動向を把握し、より大きな市場シェアを獲得するのに役立ちます。本レポートを入手した企業は、以下に概説する5つの戦略のうち、1つ以上を実行できます。
本レポートは、以下の点について洞察を提供します。
バイオチップ市場の成長に影響を与える主要な推進要因（個別化医療の需要増加、マイクロフルイディクスとAI統合における技術進歩）、制約要因（バイオチップの開発・製造コストの高騰、データ管理と標準化の問題）、機会（ポイントオブケアおよび分散診断におけるアプリケーションの拡大、ゲノミクス研究への政府および民間投資の増加）、課題（技術的な複雑さと多分野にわたる技術の統合、臨床利用における規制および検証のハードル）を分析します。
- 製品開発／イノベーション：バイオチップ市場における今後の技術と新製品投入に関する詳細な洞察。
- 市場開発：有望な新興市場に関する包括的な情報。本レポートでは、様々な地域における様々なタイプのバイオチップ市場を分析しています。
- 市場多様化：バイオチップ市場における製品、未開拓地域、最近の動向、投資に関する包括的な情報。
- 競合評価：バイオチップ市場における主要企業の市場シェア、戦略、製品、流通ネットワーク、製造能力に関する詳細な評価。
Report Description
The biochips market is expected to grow from USD 14.01 billion in 2025 to USD 21.36 billion by 2030, at a CAGR of 8.8%. This growth is driven by several key factors shaping the future of diagnostics, genomics, and personalized medicine.
A major driver of this growth is the increasing demand for precision diagnostics and personalized treatments, fueled by advancements in genomics and the growing focus on individualized healthcare. As the healthcare industry shifts toward more tailored treatment plans, the adoption of biochips for applications like genetic testing, disease detection, and drug development is rapidly expanding.
Additionally, the growing demand for faster and more efficient diagnostics is driving the need for high-throughput, point-of-care testing solutions. Biochips, particularly DNA chips and lab-on-a-chip systems, play a crucial role in meeting this demand by providing rapid, cost-effective, and scalable diagnostic solutions. The ongoing trend toward decentralization in healthcare, where diagnostic tests and treatments are moving from centralized laboratories to more accessible settings, further boosts the adoption of biochips.
Technological advancements, such as the integration of artificial intelligence for data analysis and the development of microfluidic platforms, are also accelerating market growth. These innovations enhance the accuracy, speed, and ease of use of biochip systems, expanding their applications across various sectors, from research to clinical diagnostics.
Overall, the combination of rising healthcare demands, technological innovations, and the increasing shift toward personalized and decentralized healthcare is driving robust growth in the biochips market.
By product & service, the software & services segment is projected to grow at the highest CAGR during the forecast period.
The software & services segment is expected to see the highest growth in the biochips market, driven by the increasing need for advanced data analysis, AI-driven insights, and cloud integration in biochip applications. As biochips generate large volumes of complex biological data, sophisticated software solutions are essential for processing, interpreting, and visualizing results. Additionally, the rise in personalized medicine and precision diagnostics requires bioinformatics services to handle and analyze genetic, proteomic, and genomic data. These trends, coupled with the growing adoption of cloud-based platforms for data sharing and remote diagnostics, are driving the rapid growth of software and services in the biochips market.
By end user, the biotechnology and pharmaceutical companies segment accounted for the largest market share in 2024.
In 2024, the veterinary clinics segment dominated the biochips market due to the critical role biochips play in drug discovery, genomic research, and personalized medicine. These companies use biochips for high-throughput screening, biomarker discovery, and genetic profiling, which are essential for developing new therapies and improving treatment precision. The need for faster, more accurate, and cost-effective diagnostics and research tools drives strong demand for biochips in these industries. Additionally, biochips enable pharmaceutical companies to streamline drug development processes, making them an indispensable technology in the biotech and pharmaceutical sectors.
The Asia Pacific region is expected to witness the highest growth during the forecast period.
The Asia Pacific is poised to experience the highest growth in the biochips market, driven by rapid advancements in healthcare infrastructure, increasing government investments in biotechnology, and a growing focus on personalized medicine. The region’s expanding pharmaceutical and biotechnology industries are driving demand for biochips in drug development, diagnostics, and genomic research. Additionally, rising healthcare awareness, improved healthcare access, and a growing middle class in countries such as China and India are accelerating the adoption of advanced diagnostic technologies, including biochips. This combination of economic growth, technological advancements, and healthcare innovations is driving the region’s rapid market expansion.
Breakdown of supply-side primary interviews:
- By Company Type: Tier 1 (45%), Tier 2 (20%), and Tier 3 (35%)
- By Designation: C-level Executives (35%), Directors (25%), and Other Designations (40%)
- By Region: North America (40%), Europe (25%), Asia Pacific (20%), Latin America (10%), and Middle East & Africa (5%)
Breakdown of demand-side primary interviews:
- By End User: Biotechnology and Pharmaceutical Companies (40%), Hospitals and Diagnostic Centers (25%), Academic & Research Institutes (20%), Contract Research Organizations (CROs) (10%), and Other End Users (5%)
- By Designation: Laboratory Managers / Heads (47%), Clinical Diagnostics Managers (22%), Genomics / Research Scientists (15%), and Others (16%)
- By Region: North America (25%), Europe (24%), Asia Pacific (25%), Latin America (11%), and the Middle East & Africa (15%)
Research Coverage
The market study covers the biochips market in various segments. It aims to estimate the market size and growth potential of this market by products & services, type, fabrication technology, end user, and region. The study also includes an in-depth competitive analysis of the key players in the market, along with their company profiles, key observations related to their products and business offerings, recent developments, and key market strategies.
Reasons to Buy the Report
The report can assist established companies and newer or smaller firms in understanding market trends, enabling them to capture a larger market share. Firms that acquire the report can implement one or more of the five strategies outlined below.
This report provides insights into the following points:
- Analysis of key drivers (Growing demand for personalized medicines, Technological advancements in microfluidics and AI integration), restraints (High cost of biochip development and fabrication, Data management and standardization issues), opportunities (Expanding applications in point-of-care and decentralized diagnostics, Increasing government and private investments in genomics research), and challenges (Technical complexity and integration of multidisciplinary technologies, Regulatory and validation hurdles for clinical use) influencing the growth of the biochips market.
- Product Development/Innovation: Detailed insights on upcoming technologies and product launches in the biochips market.
- Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various types of biochips across regions.
- Market Diversification: Exhaustive information about products, untapped regions, recent developments, and investments in the biochips market.
- Competitive Assessment: In-depth assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of the leading players in the biochips market.
Table of Contents
1 INTRODUCTION 31
1.1 STUDY OBJECTIVES 31
1.2 MARKET DEFINITION 31
1.3 STUDY SCOPE 31
1.3.1 MARKET SEGMENTATION AND REGIONAL SCOPE 32
1.3.2 INCLUSIONS AND EXCLUSIONS 33
1.3.3 YEARS CONSIDERED 34
1.4 STAKEHOLDERS 34
1.5 SUMMARY OF CHANGES 35
2 RESEARCH METHODOLOGY 37
2.1 RESEARCH DATA 37
2.2 RESEARCH METHODOLOGY 37
2.2.1 SECONDARY DATA 38
2.2.1.1 Key data from secondary sources 39
2.2.2 PRIMARY DATA 39
2.2.2.1 Key data from primary sources 40
2.2.2.2 Key industry insights 41
2.3 MARKET SIZE ESTIMATION 43
2.3.1 BOTTOM-UP APPROACH 48
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 49
2.5 MARKET SHARE ANALYSIS 50
2.5.1 RESEARCH ASSUMPTIONS 51
2.5.2 GROWTH RATE ASSUMPTIONS 51
2.6 RESEARCH LIMITATIONS 51
2.6.1 METHODOLOGY-RELATED LIMITATIONS 51
2.6.2 SCOPE-RELATED LIMITATIONS 52
2.7 RISK ASSESSMENT 52
3 EXECUTIVE SUMMARY 53
4 PREMIUM INSIGHTS 58
4.1 BIOCHIPS MARKET OVERVIEW 58
4.2 ASIA PACIFIC: BIOCHIPS MARKET, BY PRODUCTS & SERVICES & COUNTRY (2024) 59
4.3 BIOCHIPS MARKET: REGIONAL MIX 60
4.4 BIOCHIPS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 60
4.5 BIOCHIPS MARKET: DEVELOPED MARKETS VS. EMERGING ECONOMIES 61
5 MARKET OVERVIEW 62
5.1 INTRODUCTION 62
5.2 MARKET DYNAMICS 62
5.2.1 DRIVERS 63
5.2.1.1 Rising adoption of personalized medicine 63
5.2.1.2 Technological advancements in microarray and
microfluidics fabrication 63
5.2.1.3 Increasing R&D investments in genomics and proteomics 64
5.2.1.4 Advancements in point-of-care diagnostics and lab-on-a-chip technologies 65
5.2.2 RESTRAINTS 65
5.2.2.1 High cost of instruments and fabrication 65
5.2.2.2 Complex data interpretation and standardization 66
5.2.3 OPPORTUNITIES 66
5.2.3.1 Integration of AI and bioinformatics in biochip data analysis 66
5.2.3.2 Expansion into emerging markets and new applications 67
5.2.4 CHALLENGES 68
5.2.4.1 Technical complexity and integration of multidisciplinary technologies 68
5.2.4.2 Regulatory and validation hurdles for clinical use 68
5.3 INDUSTRY TRENDS 69
5.3.1 MINIATURIZATION, PORTABILITY, AND DECENTRALIZED DIAGNOSTICS 69
5.3.2 SHIFT TOWARD MICROFLUIDICS AND LAB-ON-A-CHIP FORMATS 70
5.4 TECHNOLOGY ANALYSIS 70
5.4.1 KEY TECHNOLOGIES 70
5.4.1.1 Digital microfluidic biochips 70
5.4.1.2 Plasmonic and nanoplasmonic biochips 71
5.4.1.3 Wearable and implantable biochips 72
5.4.2 ADJACENT TECHNOLOGIES 72
5.4.2.1 AI/Machine learning for biochip data & design 72
5.4.2.2 Optical genome mapping chips 73
5.4.3 COMPLEMENTARY TECHNOLOGIES 74
5.4.3.1 Advanced microfabrication and 3D printing 74
5.4.3.2 Biochip integration in biosensors 74
5.5 PORTER’S FIVE FORCES ANALYSIS 75
5.5.1 THREAT OF NEW ENTRANTS 77
5.5.2 THREAT OF SUBSTITUTES 77
5.5.3 BARGAINING POWER OF SUPPLIERS 77
5.5.4 BARGAINING POWER OF BUYERS 78
5.5.5 INTENSITY OF COMPETITIVE RIVALRY 78
5.6 REGULATORY LANDSCAPE 78
5.6.1 REGULATORY ANALYSIS 78
5.6.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 79
5.7 PATENT ANALYSIS 81
5.7.1 PATENT PUBLICATION TRENDS FOR BIOCHIPS 81
5.7.2 JURISDICTION AND TOP APPLICANT ANALYSIS 82
5.8 TRADE ANALYSIS 85
5.8.1 IMPORT DATA FOR HS CODE 9027 85
5.8.2 EXPORT DATA FOR HS CODE 9027 85
5.9 PRICING ANALYSIS 86
5.9.1 AVERAGE SELLING PRICE TREND, BY KEY PLAYER 86
5.9.2 AVERAGE SELLING PRICE TREND, BY REGION 87
5.9.2.1 Average selling price of DNA chips and lab-on-a-chip, by region 88
5.9.2.2 Average selling price trend of DNA chips, by region 88
5.9.2.3 Average selling price trend of lab-on-a-chip, by region 88
5.9.2.4 Average selling price trend of protein chips, by region 89
5.10 KEY CONFERENCES AND EVENTS, 2025–2026 89
5.11 KEY STAKEHOLDERS AND BUYING CRITERIA 90
5.11.1 KEY STAKEHOLDERS IN BUYING PROCESS 90
5.11.2 BUYING CRITERIA 91
5.12 END-USER ANALYSIS AND UNMET NEEDS 93
5.13 IMPACT OF AI/GENERATIVE AI ON BIOCHIPS MARKET 93
5.13.1 INTRODUCTION 93
5.13.2 MARKET POTENTIAL IN BIOCHIPS ECOSYSTEM 94
5.13.3 AI-USE CASES 94
5.13.4 KEY COMPANIES IMPLEMENTING AI IN BIOCHIPS MARKET 95
5.14 ECOSYSTEM ANALYSIS 95
5.15 CASE STUDY ANALYSIS 96
5.15.1 MICROFLUIDIC BIOCHIP-BASED MULTIPLEXED PROFILING
FOR EARLY CANCER DETECTION 96
5.15.2 POINT-OF-CARE TUMOR MARKER DETECTION BIOCHIP 97
5.15.3 GRAPHENE QUANTUM DOT-BASED BIOCHIP FOR CHILDHOOD LEUKEMIA DETECTION 97
5.16 VALUE CHAIN ANALYSIS 98
5.17 SUPPLY CHAIN ANALYSIS 99
5.18 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 101
5.19 INVESTMENT AND FUNDING SCENARIO 102
5.20 US TARIFF IMPACT ON BIOCHIPS MARKET 103
5.20.1 INTRODUCTION 103
5.20.2 KEY TARIFF RATES 104
5.20.3 PRICE IMPACT ANALYSIS 104
5.20.4 IMPACT ON COUNTRY/REGION 105
5.20.5 IMPACT ON END-USE INDUSTRIES 107
5.20.5.1 Biotechnology and pharmaceutical companies 107
5.20.5.2 Hospitals and diagnostic centers 108
5.20.5.3 Academic & research institutes 108
5.20.5.4 Contract Research Organizations (CROs) 108
5.20.5.5 Other end users 108
6 BIOCHIPS MARKET, BY PRODUCTS & SERVICES 109
6.1 INTRODUCTION 110
6.2 CONSUMABLES 112
6.2.1 SURGE IN APPLICATIONS ACROSS PERSONALIZED MEDICINE AND PRECISION DIAGNOSTICS TO AID GROWTH 112
6.3 INSTRUMENTS 114
6.3.1 RISING DEMAND FOR ADVANCED INSTRUMENTS TO ENHANCE
PRECISION AND EFFICIENCY TO DRIVE MARKET 114
6.4 SOFTWARE & SERVICES 116
6.4.1 INCREASING NEED FOR ADVANCED DATA ANALYSIS AND
BIOINFORMATICS TO SUPPORT GROWTH 116
7 BIOCHIPS MARKET, BY TYPE 118
7.1 INTRODUCTION 119
7.2 DNA CHIPS 119
7.2.1 GLOBAL VOLUME ANALYSIS OF DNA CHIPS, 2023–2030 (THOUSAND UNITS) 121
7.2.2 DNA CHIPS MARKET, BY APPLICATION 121
7.2.2.1 Gene expression 122
7.2.2.1.1 Increasing cancer incidence and rising funding for genomic research to foster growth 122
7.2.2.2 SNP genotyping 124
7.2.2.2.1 Growing adoption of genetic screening programs and direct-to-consumer genomics services to fuel market 124
7.2.2.3 Cancer diagnostics & treatment 126
7.2.2.3.1 Rising global cancer burden and expanding reimbursement coverage to spur growth 126
7.2.2.4 Genomics 128
7.2.2.4.1 Rise of personalized medicine and increasing need for non-invasive diagnostics to facilitate growth 128
7.2.2.5 Drug discovery 130
7.2.2.5.1 Increasing application of DNA chips in drug discovery to identify targets and optimize therapeutics to boost market 130
7.2.2.6 Agricultural biotechnology 132
7.2.2.6.1 Growing use of DNA chips for crop improvement and trait analysis to propel market 132
7.2.2.7 Other DNA chip applications 134
7.3 LAB-ON-A-CHIP 136
7.3.1 GLOBAL VOLUME ANALYSIS OF LAB-ON-A-CHIP,
2023–2030 (THOUSAND UNITS) 138
7.3.2 LAB-ON-A-CHIP MARKET, BY APPLICATION 138
7.3.2.1 Clinical diagnostics 138
7.3.2.1.1 Rising burden of chronic and infectious diseases to accelerate growth 138
7.3.2.2 Genomics 141
7.3.2.2.1 Increasing proliferation of genomic testing programs to stimulate growth 141
7.3.2.3 IVD & POC 143
7.3.2.3.1 Growing emphasis on early disease detection, chronic disease monitoring, and home-based testing to fuel market 143
7.3.2.4 Proteomics 145
7.3.2.4.1 Rise in biologic and biosimilar development to contribute to growth 145
7.3.2.5 Drug discovery 147
7.3.2.5.1 Increasing demand for high-throughput screening to augment growth 147
7.3.2.6 Other LOAC applications 149
7.4 PROTEIN CHIPS 151
7.4.1 GLOBAL VOLUME ANALYSIS OF PROTEIN CHIPS, 2023–2030 (THOUSAND UNITS) 153
7.4.2 PROTEIN CHIPS MARKET, BY APPLICATION 153
7.4.2.1 Proteomics 154
7.4.2.1.1 Increasing focus on large-scale protein profiling to aid growth 154
7.4.2.2 Expression profiling 156
7.4.2.2.1 Surge in demand for systems-level understanding of cellular processes to support growth 156
7.4.2.3 Diagnostics 158
7.4.2.3.1 Increasing integration of protein-chip technology into clinical diagnostic workflows to encourage growth 158
7.4.2.4 High-throughput screening 160
7.4.2.4.1 Rising demand for rapid target validation and growing complexity of biologic therapeutics to drive market 160
7.4.2.5 Drug discovery 162
7.4.2.5.1 Need for efficient target identification and screening to favor growth 162
7.4.2.6 Other protein chip applications 164
7.5 TISSUE ARRAYS 166
7.5.1 INCREASING DEMAND FOR LARGE-SCALE VALIDATION OF BIOMARKERS TO SPUR GROWTH 166
7.5.2 GLOBAL VOLUME ANALYSIS OF TISSUE ARRAYS,
2023–2030 (THOUSAND UNITS) 168
7.6 CELL ARRAYS 168
7.6.1 EXPANDING USE OF CELL ARRAYS FOR HIGH-THROUGHPUT CELLULAR ANALYSIS AND DRUG SCREENING TO AID GROWTH 168
7.6.2 GLOBAL VOLUME ANALYSIS OF CELL ARRAYS, 2023–2030 (THOUSAND UNITS) 170
8 BIOCHIPS MARKET, BY FABRICATION TECHNOLOGY 171
8.1 INTRODUCTION 172
8.2 MICROARRAYS 172
8.2.1 WIDESPREAD ADOPTION OF MICROARRAYS IN GENOMIC AND PROTEOMIC RESEARCH TO FUEL MARKET 172
8.3 MICROFLUIDICS 175
8.3.1 GROWING DEMAND FOR DECENTRALIZED, POINT-OF-CARE DIAGNOSTICS, AND HIGH-THROUGHPUT SCREENING TOOLS TO DRIVE MARKET 175
9 BIOCHIPS MARKET, BY END USER 177
9.1 INTRODUCTION 178
9.2 BIOTECHNOLOGY & PHARMACEUTICAL COMPANIES 178
9.2.1 RISING TREND OF PERSONALIZED AND PRECISION THERAPEUTICS TO EXPEDITE GROWTH 178
9.3 HOSPITALS & DIAGNOSTIC CENTERS 180
9.3.1 INCREASING HOSPITAL INVESTMENTS IN MOLECULAR PATHOLOGY TO EXPEDITE GROWTH 180
9.4 ACADEMIC & RESEARCH INSTITUTES 182
9.4.1 GROWING USE OF BIOCHIPS IN GENE-FUNCTION RELATIONSHIPS, PROTEIN NETWORKS, AND DISEASE MECHANISMS TO BOOST MARKET 182
9.5 CONTRACT RESEARCH ORGANIZATIONS (CROS) 184
9.5.1 INCREASING TREND OF OUTSOURCING RESEARCH AND DEVELOPMENT ACTIVITIES TO PROMOTE GROWTH 184
9.6 OTHER END USERS 186
10 BIOCHIPS MARKET, BY REGION 188
10.1 INTRODUCTION 189
10.2 NORTH AMERICA 190
10.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 190
10.2.2 NORTH AMERICA: VOLUME ANALYSIS, BY TYPE,
2023–2030 (THOUSAND UNITS) 192
10.2.3 US 195
10.2.3.1 Presence of prominent companies and high cancer prevalence to expedite growth 195
10.2.4 CANADA 199
10.2.4.1 Expanding genomics and precision medicine
initiatives to drive market 199
10.3 EUROPE 202
10.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 203
10.3.2 EUROPE: VOLUME ANALYSIS, BY TYPE, 2023–2030 (THOUSAND UNITS) 203
10.3.3 GERMANY 207
10.3.3.1 Robust ecosystem of biotech startups and multinational corporations to promote growth 207
10.3.4 UK 210
10.3.4.1 Increasing healthcare investments and genomic advancements to drive market 210
10.3.5 FRANCE 214
10.3.5.1 Strong government initiatives in biotechnology, precision medicine, and healthcare innovations to boost market 214
10.3.6 ITALY 217
10.3.6.1 Growing demand for precision medicine to spur growth 217
10.3.7 SPAIN 221
10.3.7.1 Increasing demand for personalized medicine and strong governmental & institutional support to propel market 221
10.3.8 NETHERLANDS 224
10.3.8.1 Increasing emphasis on genomics and personalized medicine to favor growth 224
10.3.9 REST OF EUROPE 228
10.4 ASIA PACIFIC 231
10.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 232
10.4.2 ASIA PACIFIC: VOLUME ANALYSIS, BY TYPE, 2023–2030 (THOUSAND UNITS) 233
10.4.3 CHINA 237
10.4.3.1 Rising healthcare demand to support growth 237
10.4.4 JAPAN 241
10.4.4.1 Increasing geriatric population to drive market 241
10.4.5 INDIA 244
10.4.5.1 Strong government support for domestic biotech manufacturing to facilitate growth 244
10.4.6 AUSTRALIA 248
10.4.6.1 Increasing advancements in biotechnology to spur growth 248
10.4.7 SOUTH KOREA 251
10.4.7.1 Increasing healthcare expenditure to expedite growth 251
10.4.8 THAILAND 254
10.4.8.1 Rising healthcare investments to accelerate growth 254
10.4.9 NEW ZEALAND 257
10.4.9.1 Increasing focus on early detection and improving survival rates to drive market 257
10.4.10 REST OF ASIA PACIFIC 260
10.5 LATIN AMERICA 263
10.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 263
10.5.2 LATIN AMERICA: VOLUME ANALYSIS, BY TYPE,
2023–2030 (THOUSAND UNITS) 264
10.5.3 BRAZIL 267
10.5.3.1 Increasing demand for precision medicine and advancements in genomics to foster growth 267
10.5.4 MEXICO 271
10.5.4.1 Rising prevalence of chronic and infectious conditions to contribute to growth 271
10.5.5 REST OF LATIN AMERICA 274
10.6 MIDDLE EAST & AFRICA 278
10.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 278
10.6.2 MIDDLE EAST & AFRICA: VOLUME ANALYSIS, BY TYPE, 2023–2030 (THOUSAND UNITS) 279
10.6.3 GCC COUNTRIES 282
10.6.3.1 Kingdom of Saudi Arabia (KSA) 285
10.6.3.1.1 Strong public healthcare funding and rapid expansion of hospital infrastructure to aid growth 285
10.6.3.2 United Arab Emirates (UAE) 289
10.6.3.2.1 Growing integration of advanced diagnostic technologies to fuel market 289
10.6.3.3 Rest of GCC Countries 293
10.6.4 REST OF MIDDLE EAST & AFRICA 296
11 COMPETITIVE LANDSCAPE 300
11.1 OVERVIEW 300
11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 300
11.3 REVENUE SHARE ANALYSIS, 2020–2024 302
11.4 MARKET SHARE ANALYSIS, 2024 303
11.4.1 GLOBAL MARKET SHARE ANALYSIS, 2024 304
11.4.2 US MARKET SHARE ANALYSIS, 2024 306
11.5 COMPANY VALUATION AND FINANCIAL METRICS 307
11.5.1 COMPANY VALUATION 307
11.5.2 FINANCIAL METRICS 308
11.6 BRAND/PRODUCT COMPARATIVE ANALYSIS 309
11.7 R&D EXPENDITURE OF KEY PLAYERS 310
11.8 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024 310
11.8.1 STARS 310
11.8.2 EMERGING LEADERS 310
11.8.3 PERVASIVE PLAYERS 311
11.8.4 PARTICIPANTS 311
11.8.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024 312
11.8.5.1 Company footprint 312
11.8.5.2 Region footprint 313
11.8.5.3 Product & service footprint 314
11.8.5.4 Type footprint 315
11.8.5.5 Fabrication technology footprint 316
11.9 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024 316
11.9.1 PROGRESSIVE COMPANIES 316
11.9.2 RESPONSIVE COMPANIES 317
11.9.3 DYNAMIC COMPANIES 317
11.9.4 STARTING BLOCKS 317
11.9.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024 318
11.9.5.1 Detailed list of key startups/SMEs 318
11.9.5.2 Competitive benchmarking of key startups/SMEs 319
11.10 COMPETITIVE SCENARIO 319
11.10.1 PRODUCT/SERVICE LAUNCHES, ENHANCEMENTS, AND APPROVALS 319
11.10.2 DEALS 321
11.10.3 EXPANSIONS 322
11.10.4 OTHER DEVELOPMENTS 323
12 COMPANY PROFILES 324
12.1 KEY PLAYERS 324
12.1.1 THERMO FISHER SCIENTIFIC INC. 324
12.1.1.1 Business overview 324
12.1.1.2 Products/Services offered 325
12.1.1.3 Recent developments 327
12.1.1.3.1 Product/Service launches, enhancements, and approvals 327
12.1.1.4 MnM view 327
12.1.1.4.1 Key strengths 327
12.1.1.4.2 Strategic choices 328
12.1.1.4.3 Weaknesses and competitive threats 328
12.1.2 ILLUMINA, INC. 329
12.1.2.1 Business overview 329
12.1.2.2 Products/Services offered 330
12.1.2.3 Recent developments 332
12.1.2.3.1 Product/Service launches, enhancements, and approvals 332
12.1.2.3.2 Deals 332
12.1.2.4 MnM view 332
12.1.2.4.1 Key strengths 332
12.1.2.4.2 Strategic choices 333
12.1.2.4.3 Weaknesses and competitive threats 333
12.1.3 AGILENT TECHNOLOGIES, INC. 334
12.1.3.1 Business overview 334
12.1.3.2 Products/Services offered 335
12.1.3.3 Recent developments 337
12.1.3.3.1 Deals 337
12.1.3.3.2 Expansions 337
12.1.3.3.3 Other developments 338
12.1.3.4 MnM view 338
12.1.3.4.1 Key strengths 338
12.1.3.4.2 Strategic choices 338
12.1.3.4.3 Weaknesses and competitive threats 339
12.1.4 F. HOFFMANN-LA ROCHE LTD 340
12.1.4.1 Business overview 340
12.1.4.2 Products/Services offered 341
12.1.4.3 Recent developments 342
12.1.4.3.1 Product/Service launches, enhancements, and approvals 342
12.1.4.4 MnM view 343
12.1.4.4.1 Key strengths 343
12.1.4.4.2 Strategic choices 344
12.1.4.4.3 Weaknesses and competitive threats 344
12.1.5 QIAGEN 345
12.1.5.1 Business overview 345
12.1.5.2 Products/Services offered 346
12.1.5.3 Recent developments 347
12.1.5.3.1 Product/Service launches, enhancements, and approvals 347
12.1.5.3.2 Deals 349
12.1.5.3.3 Expansions 349
12.1.5.3.4 Other developments 350
12.1.5.4 MnM view 350
12.1.5.4.1 Key strengths 350
12.1.5.4.2 Strategic choices 351
12.1.5.4.3 Weaknesses and competitive threats 351
12.1.6 BIO-RAD LABORATORIES, INC. 352
12.1.6.1 Business overview 352
12.1.6.2 Products/Services offered 353
12.1.7 ABBOTT 354
12.1.7.1 Business overview 354
12.1.7.2 Products/Services offered 355
12.1.7.3 Recent developments 356
12.1.7.3.1 Product/Service launches, enhancements, and approvals 356
12.1.8 STANDARD BIOTOOLS 357
12.1.8.1 Business overview 357
12.1.8.2 Products/Services offered 358
12.1.8.3 Recent developments 360
12.1.8.3.1 Product/Service launches, enhancements, and approvals 360
12.1.8.3.2 Deals 360
12.1.8.3.3 Other developments 361
12.1.9 10X GENOMICS 362
12.1.9.1 Business overview 362
12.1.9.2 Products/Services offered 363
12.1.9.3 Recent developments 365
12.1.9.3.1 Product/Service launches, enhancements, and approvals 365
12.1.9.3.2 Deals 366
12.1.9.3.3 Other developments 367
12.1.10 CEPHEID 368
12.1.10.1 Business overview 368
12.1.10.2 Products/Services offered 368
12.1.10.3 Recent developments 370
12.1.10.3.1 Product/Service launches, enhancements, and approvals 370
12.1.10.3.2 Deals 372
12.1.10.3.3 Other developments 373
12.1.11 BIOMÉRIEUX 374
12.1.11.1 Business overview 374
12.1.11.2 Products/Services offered 375
12.1.11.2.1 Product/Service launches, enhancements, and approvals 376
12.1.11.2.2 Deals 377
12.1.12 REVVITY 378
12.1.12.1 Business overview 378
12.1.12.2 Products/Services offered 380
12.1.12.3 Recent developments 382
12.1.12.3.1 Deals 382
12.1.13 DIASORIN S.P.A. 383
12.1.13.1 Business overview 383
12.1.13.2 Products/Services offered 384
12.1.14 RANDOX LABORATORIES LTD. 386
12.1.14.1 Business overview 386
12.1.14.2 Products/Services offered 386
12.1.14.3 Recent developments 388
12.1.14.3.1 Product/Service launches, enhancements, and approvals 388
12.1.14.3.2 Deals 388
12.1.14.3.3 Expansions 389
12.1.15 OXFORD GENE TECHNOLOGY IP LIMITED 390
12.1.15.1 Business overview 390
12.1.15.2 Products/Services offered 390
12.2 OTHER PLAYERS 392
12.2.1 MICRONIT B.V. 392
12.2.2 RAYBIOTECH, INC. 393
12.2.3 PHALANX BIOTECH GROUP 394
12.2.4 ARRAYIT CORPORATION 395
12.2.5 3DHISTECH LTD. 396
12.2.6 CREATIVE BIOARRAY 397
12.2.7 TISSUEARRAY.COM 399
12.2.8 IBIOCHIPS 400
12.2.9 CAPITALBIOTECH CO., LTD. 401
12.2.10 PEPPERPRINT GMBH 402
13 APPENDIX 403
13.1 DISCUSSION GUIDE 403
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 407
13.3 CUSTOMIZATION OPTIONS 409
13.3.1 PRODUCT ANALYSIS 409
13.3.2 COMPANY INFORMATION 409
13.3.3 GEOGRAPHIC ANALYSIS 409
13.3.4 REGIONAL/COUNTRY-LEVEL MARKET SHARE ANALYSIS 409
13.3.5 COUNTRY-LEVEL VOLUME ANALYSIS BY PRODUCT 409
13.3.6 BY PRODUCT MARKET SHARE ANALYSIS (TOP 5 PLAYERS) 409
13.3.7 ANY CONSULT/CUSTOM REQUIREMENTS AS PER CLIENT REQUESTS 409
13.4 RELATED REPORTS 410
13.5 AUTHOR DETAILS 411
LIST OF TABLES
TABLE 1 BIOCHIPS MARKET: INCLUSIONS AND EXCLUSIONS 33
TABLE 2 STANDARD CURRENCY CONVERSION RATES, 2021–2024 (UNIT OF USD) 34
TABLE 3 BIOCHIPS MARKET: RISK ASSESSMENT 52
TABLE 4 BIOCHIPS MARKET: PORTER’S FIVE FORCES ANALYSIS 76
TABLE 5 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 79
TABLE 6 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 80
TABLE 7 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 80
TABLE 8 BIOCHIPS MARKET: MAJOR PATENTS, 2022–2025 83
TABLE 9 IMPORT DATA FOR HS CODE 9027, BY COUNTRY, 2020–2024 (USD THOUSANDS) 85
TABLE 10 EXPORT DATA FOR HS CODE 9027, BY COUNTRY, 2020–2024 (USD THOUSANDS) 85
TABLE 11 AVERAGE SELLING PRICE TREND OF BIOCHIPS, BY KEY PLAYER, 2022–2024 86
TABLE 12 AVERAGE SELLING PRICE TREND OF DNA CHIPS, BY REGION, 2022–2024 88
TABLE 13 AVERAGE SELLING PRICE TREND FOR LAB-ON-A-CHIP, BY REGION, 2022–2024 88
TABLE 14 AVERAGE SELLING PRICE TREND OF PROTEIN CHIPS, BY REGION, 2022–2024 89
TABLE 15 BIOCHIPS MARKET: KEY CONFERENCES AND EVENTS, 2025–2026 89
TABLE 16 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR BIOCHIPS, BY PRODUCT 91
TABLE 17 KEY BUYING CRITERIA FOR TOP THREE END USERS 92
TABLE 18 KEY COMPANIES IMPLEMENTING AI IN BIOCHIPS MARKET 95
TABLE 19 US ADJUSTED RECIPROCAL TARIFF RATES 104
TABLE 20 KEY PRODUCT-RELATED TARIFF EFFECTIVE BIOCHIPS 104
TABLE 21 NORTH AMERICA: IMPACT ON CANADA DUE TO US TARIFFS 105
TABLE 22 ASIA PACIFIC: IMPACT ON CHINA, JAPAN, AND INDIA DUE TO US TARIFFS 106
TABLE 23 EUROPE: IMPACT ON GERMANY AND UK DUE TO THE US TARIFFS 107
TABLE 24 LATIN AMERICA: IMPACT ON MEXICO DUE TO US TARIFFS 107
TABLE 25 BIOCHIPS MARKET, BY PRODUCTS & SERVICES, 2023–2030 (USD MILLION) 110
TABLE 26 BIOCHIPS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 111
TABLE 27 KEY PLAYERS PROVIDING BIOCHIP CONSUMABLES 112
TABLE 28 BIOCHIPS MARKET FOR CONSUMABLES, BY COUNTRY, 2023–2030 (USD MILLION) 113
TABLE 29 KEY PLAYERS PROVIDING BIOCHIP INSTRUMENTS 114
TABLE 30 BIOCHIPS MARKET FOR INSTRUMENTS, BY COUNTRY, 2023–2030 (USD MILLION) 115
TABLE 31 KEY PLAYERS PROVIDING BIOCHIPS SOFTWARE & SERVICES 116
TABLE 32 BIOCHIPS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2023–2030 (USD MILLION) 117
TABLE 33 BIOCHIPS MARKET, BY TYPE, 2023–2030 (USD MILLION) 119
TABLE 34 DNA CHIPS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 120
TABLE 35 GLOBAL VOLUME ANALYSIS OF DNA CHIPS, 2023–2030 (THOUSAND UNITS) 121
TABLE 36 DNA CHIPS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 121
TABLE 37 KEY PLAYERS PROVIDING DNA CHIPS FOR GENE EXPRESSION 122
TABLE 38 DNA CHIPS MARKET FOR GENE EXPRESSION, BY COUNTRY, 2023–2030 (USD MILLION) 123
TABLE 39 KEY PLAYERS PROVIDING DNA CHIPS FOR SNP GENOTYPING 124
TABLE 40 DNA CHIPS MARKET FOR SNP GENOTYPING, BY COUNTRY, 2023–2030 (USD MILLION) 125
TABLE 41 KEY PLAYERS PROVIDING DNA CHIPS FOR CANCER DIAGNOSTICS & TREATMENT 126
TABLE 42 DNA CHIPS MARKET FOR CANCER DIAGNOSTICS & TREATMENT, BY COUNTRY, 2023–2030 (USD MILLION) 127
TABLE 43 KEY PLAYERS PROVIDING DNA CHIPS FOR GENOMICS 128
TABLE 44 DNA CHIPS MARKET FOR GENOMICS, BY COUNTRY, 2023–2030 (USD MILLION) 129
TABLE 45 DNA CHIPS MARKET FOR DRUG DISCOVERY, BY COUNTRY, 2023–2030 (USD MILLION) 131
TABLE 46 DNA CHIPS MARKET FOR AGRICULTURAL BIOTECHNOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 133
TABLE 47 DNA CHIPS MARKET FOR OTHER DNA CHIP APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 135
TABLE 48 LAB-ON-A-CHIP MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 137
TABLE 49 GLOBAL VOLUME ANALYSIS OF LAB-ON-A-CHIP, 2023–2030 (THOUSAND UNITS) 138
TABLE 50 LAB-ON-A-CHIP MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 138
TABLE 51 KEY PLAYERS PROVIDING LAB-ON-A-CHIP FOR CLINICAL DIAGNOSTIC 139
TABLE 52 LAB-ON-A-CHIP MARKET FOR CLINICAL DIAGNOSTIC, BY COUNTRY, 2023–2030 (USD MILLION) 140
TABLE 53 KEY PLAYERS PROVIDING LAB-ON-A-CHIP FOR GENOMICS 141
TABLE 54 LAB-ON-A-CHIP MARKET FOR GENOMICS, BY COUNTRY, 2023–2030 (USD MILLION) 142
TABLE 55 KEY PLAYERS PROVIDING LAB-ON-A-CHIP FOR IVD & POC 143
TABLE 56 LAB-ON-A-CHIP MARKET FOR IVD & POC, BY COUNTRY, 2023–2030 (USD MILLION) 144
TABLE 57 KEY PLAYERS PROVIDING LAB-ON-A-CHIP FOR PROTEOMICS 145
TABLE 58 LAB-ON-A-CHIP MARKET FOR PROTEOMICS, BY COUNTRY, 2023–2030 (USD MILLION) 146
TABLE 59 LAB-ON-A-CHIP MARKET FOR DRUG DISCOVERY, BY COUNTRY, 2023–2030 (USD MILLION) 148
TABLE 60 LAB-ON-A-CHIP MARKET FOR OTHER LOAC APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 150
TABLE 61 PROTEIN CHIPS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 152
TABLE 62 GLOBAL VOLUME ANALYSIS OF PROTEIN CHIPS, 2023–2030 (THOUSAND UNITS) 153
TABLE 63 PROTEIN CHIPS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 153
TABLE 64 KEY PLAYERS PROVIDING PROTEIN CHIPS FOR PROTEOMICS 154
TABLE 65 PROTEIN CHIPS MARKET FOR PROTEOMICS, BY COUNTRY,
2023–2030 (USD MILLION) 155
TABLE 66 KEY PLAYERS PROVIDING PROTEIN CHIPS FOR EXPRESSION PROFILING 156
TABLE 67 PROTEIN CHIPS MARKET FOR EXPRESSION PROFILING, BY COUNTRY,
2023–2030 (USD MILLION) 157
TABLE 68 KEY PLAYERS PROVIDING PROTEIN CHIPS FOR DIAGNOSTICS 158
TABLE 69 PROTEIN CHIPS MARKET FOR DIAGNOSTICS, BY COUNTRY,
2023–2030 (USD MILLION) 159
TABLE 70 KEY PLAYERS PROVIDING PROTEIN CHIPS FOR HIGH-THROUGHPUT SCREENING 160
TABLE 71 PROTEIN CHIPS MARKET FOR HIGH-THROUGHPUT SCREENING,
BY COUNTRY, 2023–2030 (USD MILLION) 161
TABLE 72 PROTEIN CHIPS MARKET FOR DRUG DISCOVERY, BY COUNTRY,
2023–2030 (USD MILLION) 163
TABLE 73 PROTEIN CHIPS MARKET FOR OTHER PROTEIN CHIP APPLICATIONS,
BY COUNTRY, 2023–2030 (USD MILLION) 165
TABLE 74 KEY PLAYERS PROVIDING TISSUE ARRAYS 166
TABLE 75 TISSUE ARRAYS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 167
TABLE 76 GLOBAL VOLUME ANALYSIS OF TISSUE ARRAYS, 2023–2030 (THOUSAND UNITS) 168
TABLE 77 KEY PLAYERS PROVIDING CELL ARRAYS 168
TABLE 78 BIOCHIPS MARKET FOR CELL ARRAYS, BY COUNTRY, 2023–2030 (USD MILLION) 169
TABLE 79 GLOBAL VOLUME ANALYSIS OF CELL ARRAYS, 2023–2030 (THOUSAND UNITS) 170
TABLE 80 BIOCHIPS MARKET, BY FABRICATION TECHNOLOGY, 2023–2030 (USD MILLION) 172
TABLE 81 KEY PLAYERS PROVIDING BIOCHIP MICROARRAYS 173
TABLE 82 BIOCHIPS MARKET FOR MICROARRAYS, BY COUNTRY, 2023–2030 (USD MILLION) 174
TABLE 83 KEY PLAYERS PROVIDING MICROFLUIDICS 175
TABLE 84 BIOCHIPS MARKET FOR MICROFLUIDICS, BY COUNTRY,
2023–2030 (USD MILLION) 176
TABLE 85 BIOCHIPS MARKET, BY END USER, 2023–2030 (USD MILLION) 178
TABLE 86 BIOCHIPS MARKET FOR BIOTECHNOLOGY AND PHARMACEUTICAL COMPANIES,
BY COUNTRY, 2023–2030 (USD MILLION) 179
TABLE 87 BIOCHIPS MARKET FOR HOSPITALS & DIAGNOSTIC CENTERS, BY COUNTRY,
2023–2030 (USD MILLION) 181
TABLE 88 BIOCHIPS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY,
2023–2030 (USD MILLION) 183
TABLE 89 BIOCHIPS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS (CROS),
BY COUNTRY, 2023–2030 (USD MILLION) 185
TABLE 90 BIOCHIPS MARKET FOR OTHER END USERS, BY COUNTRY,
2023–2030 (USD MILLION) 187
TABLE 91 BIOCHIPS MARKET, BY REGION, 2023–2030 (USD MILLION) 190
TABLE 92 NORTH AMERICA: VOLUME ANALYSIS, BY TYPE, 2023–2030 (THOUSAND UNITS) 192
TABLE 93 NORTH AMERICA: BIOCHIPS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 192
TABLE 94 NORTH AMERICA: BIOCHIPS MARKET, BY PRODUCT & SERVICE,
2023–2030 (USD MILLION) 192
TABLE 95 NORTH AMERICA: BIOCHIPS MARKET, BY TYPE, 2023–2030 (USD MILLION) 193
TABLE 96 NORTH AMERICA: DNA CHIPS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 193
TABLE 97 NORTH AMERICA: LAB-ON-A-CHIP MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 194
TABLE 98 NORTH AMERICA: PROTEIN CHIPS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 194
TABLE 99 NORTH AMERICA: BIOCHIPS MARKET, BY FABRICATION TECHNOLOGY,
2023–2030 (USD MILLION) 194
TABLE 100 NORTH AMERICA: BIOCHIPS MARKET, BY END USER, 2023–2030 (USD MILLION) 195
TABLE 101 US: KEY MACROECONOMIC INDICATORS 196
TABLE 102 US: BIOCHIPS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 196
TABLE 103 US: BIOCHIPS MARKET, BY TYPE, 2023–2030 (USD MILLION) 196
TABLE 104 US: DNA CHIPS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 197
TABLE 105 US: LAB-ON-A-CHIP MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 197
TABLE 106 US: PROTEIN CHIPS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 198
TABLE 107 US: BIOCHIPS MARKET, BY FABRICATION TECHNOLOGY,
2023–2030 (USD MILLION) 198
TABLE 108 US: BIOCHIPS MARKET, BY END USER, 2023–2030 (USD MILLION) 198
TABLE 109 CANADA: KEY MACROECONOMIC INDICATORS 199
TABLE 110 CANADA: BIOCHIPS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 200
TABLE 111 CANADA: BIOCHIPS MARKET, BY TYPE, 2023–2030 (USD MILLION) 200
TABLE 112 CANADA: DNA CHIPS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 200
TABLE 113 CANADA: LAB-ON-A-CHIP MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 201
TABLE 114 CANADA: PROTEIN CHIPS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 201
TABLE 115 CANADA: BIOCHIPS MARKET, BY FABRICATION TECHNOLOGY,
2023–2030 (USD MILLION) 201
TABLE 116 CANADA: BIOCHIPS MARKET, BY END USER, 2023–2030 (USD MILLION) 202
TABLE 117 EUROPE: VOLUME ANALYSIS, BY TYPE, 2023–2030 (THOUSAND UNITS) 203
TABLE 118 EUROPE: BIOCHIPS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 204
TABLE 119 EUROPE: BIOCHIPS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 204
TABLE 120 EUROPE: BIOCHIPS MARKET, BY TYPE, 2023–2030 (USD MILLION) 204
TABLE 121 EUROPE: DNA CHIPS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 205
TABLE 122 EUROPE: LAB-ON-A-CHIP MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 205
TABLE 123 EUROPE: PROTEIN CHIPS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 206
TABLE 124 EUROPE: BIOCHIPS MARKET, BY FABRICATION TECHNOLOGY,
2023–2030 (USD MILLION) 206
TABLE 125 EUROPE: BIOCHIPS MARKET, BY END USER, 2023–2030 (USD MILLION) 206
TABLE 126 GERMANY: KEY MACROECONOMIC INDICATORS 207
TABLE 127 GERMANY: BIOCHIPS MARKET, BY PRODUCT & SERVICE,
2023–2030 (USD MILLION) 208
TABLE 128 GERMANY: BIOCHIPS MARKET, BY TYPE, 2023–2030 (USD MILLION) 208
TABLE 129 GERMANY: DNA CHIPS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 208
TABLE 130 GERMANY: LAB-ON-A-CHIP MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 209
TABLE 131 GERMANY: PROTEIN CHIPS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 209
TABLE 132 GERMANY: BIOCHIPS MARKET, BY FABRICATION TECHNOLOGY,
2023–2030 (USD MILLION) 209
TABLE 133 GERMANY: BIOCHIPS MARKET, BY END USER, 2023–2030 (USD MILLION) 210
TABLE 134 UK: KEY MACROECONOMIC INDICATORS 211
TABLE 135 UK: BIOCHIPS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 211
TABLE 136 UK: BIOCHIPS MARKET, BY TYPE, 2023–2030 (USD MILLION) 211
TABLE 137 UK: DNA CHIPS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 212
TABLE 138 UK: LAB-ON-A-CHIP MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 212
TABLE 139 UK: PROTEIN CHIPS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 213
TABLE 140 UK: BIOCHIPS MARKET, BY FABRICATION TECHNOLOGY,
2023–2030 (USD MILLION) 213
TABLE 141 UK: BIOCHIPS MARKET, BY END USER, 2023–2030 (USD MILLION) 213
TABLE 142 FRANCE: KEY MACROECONOMIC INDICATORS 214
TABLE 143 FRANCE: BIOCHIPS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 214
TABLE 144 FRANCE: BIOCHIPS MARKET, BY TYPE, 2023–2030 (USD MILLION) 214
TABLE 145 FRANCE: DNA CHIPS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 215
TABLE 146 FRANCE: LAB-ON-A-CHIP MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 216
TABLE 147 FRANCE: PROTEIN CHIPS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 216
TABLE 148 FRANCE: BIOCHIPS MARKET, BY FABRICATION TECHNOLOGY,
2023–2030 (USD MILLION) 216
TABLE 149 FRANCE: BIOCHIPS MARKET, BY END USER, 2023–2030 (USD MILLION) 217
TABLE 150 ITALY: KEY MACROECONOMIC INDICATORS 218
TABLE 151 ITALY: BIOCHIPS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 218
TABLE 152 ITALY: BIOCHIPS MARKET, BY TYPE, 2023–2030 (USD MILLION) 218
TABLE 153 ITALY: DNA CHIPS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 219
TABLE 154 ITALY: LAB-ON-A-CHIP MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 219
TABLE 155 ITALY: PROTEIN CHIPS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 220
TABLE 156 ITALY: BIOCHIPS MARKET, BY FABRICATION TECHNOLOGY,
2023–2030 (USD MILLION) 220
TABLE 157 ITALY: BIOCHIPS MARKET, BY END USER, 2023–2030 (USD MILLION) 220
TABLE 158 SPAIN: KEY MACROECONOMIC INDICATORS 221
TABLE 159 SPAIN: BIOCHIPS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 222
TABLE 160 SPAIN: BIOCHIPS MARKET, BY TYPE, 2023–2030 (USD MILLION) 222
TABLE 161 SPAIN: DNA CHIPS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 222
TABLE 162 SPAIN: LAB-ON-A-CHIP MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 223
TABLE 163 SPAIN: PROTEIN CHIPS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 223
TABLE 164 SPAIN: BIOCHIPS MARKET, BY FABRICATION TECHNOLOGY,
2023–2030 (USD MILLION) 223
TABLE 165 SPAIN: BIOCHIPS MARKET, BY END USER, 2023–2030 (USD MILLION) 224
TABLE 166 NETHERLANDS: KEY MACROECONOMIC INDICATORS 225
TABLE 167 NETHERLANDS: BIOCHIPS MARKET, BY PRODUCT & SERVICE,
2023–2030 (USD MILLION) 225
TABLE 168 NETHERLANDS: BIOCHIPS MARKET, BY TYPE, 2023–2030 (USD MILLION) 225
TABLE 169 NETHERLANDS: DNA CHIPS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 226
TABLE 170 NETHERLANDS: LAB-ON-A-CHIP MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 226
TABLE 171 NETHERLANDS: PROTEIN CHIPS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 227
TABLE 172 NETHERLANDS: BIOCHIPS MARKET, BY FABRICATION TECHNOLOGY,
2023–2030 (USD MILLION) 227
TABLE 173 NETHERLANDS: BIOCHIPS MARKET, BY END USER, 2023–2030 (USD MILLION) 228
TABLE 174 REST OF EUROPE: BIOCHIPS MARKET, BY PRODUCT & SERVICE,
2023–2030 (USD MILLION) 228
TABLE 175 REST OF EUROPE: BIOCHIPS MARKET, BY TYPE, 2023–2030 (USD MILLION) 229
TABLE 176 REST OF EUROPE: DNA CHIPS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 229
TABLE 177 REST OF EUROPE: LAB-ON-A-CHIP MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 230
TABLE 178 REST OF EUROPE: PROTEIN CHIPS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 230
TABLE 179 REST OF EUROPE: BIOCHIPS MARKET, BY FABRICATION TECHNOLOGY,
2023–2030 (USD MILLION) 231
TABLE 180 REST OF EUROPE: BIOCHIPS MARKET, BY END USER, 2023–2030 (USD MILLION) 231
TABLE 181 ASIA PACIFIC: VOLUME ANALYSIS, BY TYPE, 2023–2030 (THOUSAND UNITS) 233
TABLE 182 ASIA PACIFIC: BIOCHIPS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 234
TABLE 183 ASIA PACIFIC: BIOCHIPS MARKET, BY PRODUCT & SERVICE,
2023–2030 (USD MILLION) 234
TABLE 184 ASIA PACIFIC: BIOCHIPS MARKET, BY TYPE, 2023–2030 (USD MILLION) 235
TABLE 185 ASIA PACIFIC: DNA CHIPS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 235
TABLE 186 ASIA PACIFIC: LAB-ON-A-CHIP MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 236
TABLE 187 ASIA PACIFIC: PROTEIN CHIPS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 236
TABLE 188 ASIA PACIFIC: BIOCHIPS MARKET, BY FABRICATION TECHNOLOGY,
2023–2030 (USD MILLION) 236
TABLE 189 ASIA PACIFIC: BIOCHIPS MARKET, BY END USER, 2023–2030 (USD MILLION) 237
TABLE 190 CHINA: KEY MACROECONOMIC INDICATORS 238
TABLE 191 CHINA: BIOCHIPS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 238
TABLE 192 CHINA: BIOCHIPS MARKET, BY TYPE, 2023–2030 (USD MILLION) 238
TABLE 193 CHINA: DNA CHIPS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 239
TABLE 194 CHINA: LAB-ON-A-CHIP MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 239
TABLE 195 CHINA: PROTEIN CHIPS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 240
TABLE 196 CHINA: BIOCHIPS MARKET, BY FABRICATION TECHNOLOGY,
2023–2030 (USD MILLION) 240
TABLE 197 CHINA: BIOCHIPS MARKET, BY END USER, 2023–2030 (USD MILLION) 240
TABLE 198 JAPAN: KEY MACROECONOMIC INDICATORS 241
TABLE 199 JAPAN: BIOCHIPS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 242
TABLE 200 JAPAN: BIOCHIPS MARKET, BY TYPE, 2023–2030 (USD MILLION) 242
TABLE 201 JAPAN: DNA CHIPS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 242
TABLE 202 JAPAN: LAB-ON-A-CHIP MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 243
TABLE 203 JAPAN: PROTEIN CHIPS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 243
TABLE 204 JAPAN: BIOCHIPS MARKET, BY FABRICATION TECHNOLOGY,
2023–2030 (USD MILLION) 243
TABLE 205 JAPAN: BIOCHIPS MARKET, BY END USER, 2023–2030 (USD MILLION) 244
TABLE 206 INDIA: KEY MACROECONOMIC INDICATORS 245
TABLE 207 INDIA: BIOCHIPS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 245
TABLE 208 INDIA: BIOCHIPS MARKET, BY TYPE, 2023–2030 (USD MILLION) 245
TABLE 209 INDIA: DNA CHIPS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 246
TABLE 210 INDIA: LAB-ON-A-CHIP MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 246
TABLE 211 INDIA: PROTEIN CHIPS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 247
TABLE 212 INDIA: BIOCHIPS MARKET, BY FABRICATION TECHNOLOGY,
2023–2030 (USD MILLION) 247
TABLE 213 INDIA: BIOCHIPS MARKET, BY END USER, 2023–2030 (USD MILLION) 247
TABLE 214 AUSTRALIA: KEY MACROECONOMIC INDICATORS 248
TABLE 215 AUSTRALIA: BIOCHIPS MARKET, BY PRODUCT & SERVICE,
2023–2030 (USD MILLION) 249
TABLE 216 AUSTRALIA: BIOCHIPS MARKET, BY TYPE, 2023–2030 (USD MILLION) 249
TABLE 217 AUSTRALIA: DNA CHIPS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 249
TABLE 218 AUSTRALIA: LAB-ON-A-CHIP MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 250
TABLE 219 AUSTRALIA: PROTEIN CHIPS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 250
TABLE 220 AUSTRALIA: BIOCHIPS MARKET, BY FABRICATION TECHNOLOGY,
2023–2030 (USD MILLION) 250
TABLE 221 AUSTRALIA: BIOCHIPS MARKET, BY END USER, 2023–2030 (USD MILLION) 251
TABLE 222 SOUTH KOREA: KEY MACROECONOMIC INDICATORS 251
TABLE 223 SOUTH KOREA: BIOCHIPS MARKET, BY PRODUCT & SERVICE,
2023–2030 (USD MILLION) 252
TABLE 224 SOUTH KOREA: BIOCHIPS MARKET, BY TYPE, 2023–2030 (USD MILLION) 252
TABLE 225 SOUTH KOREA: DNA CHIPS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 252
TABLE 226 SOUTH KOREA: LAB-ON-A-CHIP MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 253
TABLE 227 SOUTH KOREA: PROTEIN CHIPS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 253
TABLE 228 SOUTH KOREA: BIOCHIPS MARKET, BY FABRICATION TECHNOLOGY,
2023–2030 (USD MILLION) 253
TABLE 229 SOUTH KOREA: BIOCHIPS MARKET, BY END USER, 2023–2030 (USD MILLION) 254
TABLE 230 THAILAND: KEY MACROECONOMIC INDICATORS 254
TABLE 231 THAILAND: BIOCHIPS MARKET, BY PRODUCT & SERVICE,
2023–2030 (USD MILLION) 255
TABLE 232 THAILAND: BIOCHIPS MARKET, BY TYPE, 2023–2030 (USD MILLION) 255
TABLE 233 THAILAND: DNA CHIPS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 255
TABLE 234 THAILAND: LAB-ON-A-CHIP MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 256
TABLE 235 THAILAND: PROTEIN CHIPS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 256
TABLE 236 THAILAND: BIOCHIPS MARKET, BY FABRICATION TECHNOLOGY,
2023–2030 (USD MILLION) 256
TABLE 237 THAILAND: BIOCHIPS MARKET, BY END USER, 2023–2030 (USD MILLION) 257
TABLE 238 NEW ZEALAND: KEY MACROECONOMIC INDICATORS 257
TABLE 239 NEW ZEALAND: BIOCHIPS MARKET, BY PRODUCT & SERVICE,
2023–2030 (USD MILLION) 258
TABLE 240 NEW ZEALAND: BIOCHIPS MARKET, BY TYPE, 2023–2030 (USD MILLION) 258
TABLE 241 NEW ZEALAND: DNA CHIPS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 258
TABLE 242 NEW ZEALAND: LAB-ON-A-CHIP MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 259
TABLE 243 NEW ZEALAND: PROTEIN CHIPS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 259
TABLE 244 NEW ZEALAND: BIOCHIPS MARKET, BY FABRICATION TECHNOLOGY,
2023–2030 (USD MILLION) 259
TABLE 245 NEW ZEALAND: BIOCHIPS MARKET, BY END USER, 2023–2030 (USD MILLION) 260
TABLE 246 REST OF ASIA PACIFIC: BIOCHIPS MARKET, BY PRODUCT & SERVICE,
2023–2030 (USD MILLION) 260
TABLE 247 REST OF ASIA PACIFIC: BIOCHIPS MARKET, BY TYPE, 2023–2030 (USD MILLION) 261
TABLE 248 REST OF ASIA PACIFIC: DNA CHIPS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 261
TABLE 249 REST OF ASIA PACIFIC: LAB-ON-A-CHIP MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 262
TABLE 250 REST OF ASIA PACIFIC: PROTEIN CHIPS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 262
TABLE 251 REST OF ASIA PACIFIC: BIOCHIPS MARKET, BY FABRICATION TECHNOLOGY,
2023–2030 (USD MILLION) 262
TABLE 252 REST OF ASIA PACIFIC: BIOCHIPS MARKET, BY END USER,
2023–2030 (USD MILLION) 263
TABLE 253 LATIN AMERICA: VOLUME ANALYSIS, BY TYPE, 2023–2030 (THOUSAND UNITS) 264
TABLE 254 LATIN AMERICA: BIOCHIPS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 264
TABLE 255 LATIN AMERICA: BIOCHIPS MARKET, BY PRODUCT & SERVICE,
2023–2030 (USD MILLION) 265
TABLE 256 LATIN AMERICA: BIOCHIPS MARKET, BY TYPE, 2023–2030 (USD MILLION) 265
TABLE 257 LATIN AMERICA: DNA CHIPS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 265
TABLE 258 LATIN AMERICA: LAB-ON-A-CHIP MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 266
TABLE 259 LATIN AMERICA: PROTEIN CHIPS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 266
TABLE 260 LATIN AMERICA: BIOCHIPS MARKET, BY FABRICATION TECHNOLOGY,
2023–2030 (USD MILLION) 267
TABLE 261 LATIN AMERICA: BIOCHIPS MARKET, BY END USER, 2023–2030 (USD MILLION) 267
TABLE 262 BRAZIL: KEY MACROECONOMIC INDICATORS 268
TABLE 263 BRAZIL: BIOCHIPS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 268
TABLE 264 BRAZIL: BIOCHIPS MARKET, BY TYPE, 2023–2030 (USD MILLION) 268
TABLE 265 BRAZIL: DNA CHIPS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 269
TABLE 266 BRAZIL: LAB-ON-A-CHIP MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 269
TABLE 267 BRAZIL: PROTEIN CHIPS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 270
TABLE 268 BRAZIL: BIOCHIPS MARKET, BY FABRICATION TECHNOLOGY,
2023–2030 (USD MILLION) 270
TABLE 269 BRAZIL: BIOCHIPS MARKET, BY END USER, 2023–2030 (USD MILLION) 270
TABLE 270 MEXICO: KEY MACROECONOMIC INDICATORS 271
TABLE 271 MEXICO: BIOCHIPS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 272
TABLE 272 MEXICO: BIOCHIPS MARKET, BY TYPE, 2023–2030 (USD MILLION) 272
TABLE 273 MEXICO: DNA CHIPS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 272
TABLE 274 MEXICO: LAB-ON-A-CHIP MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 273
TABLE 275 MEXICO: PROTEIN CHIPS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 273
TABLE 276 MEXICO: BIOCHIPS MARKET, BY FABRICATION TECHNOLOGY,
2023–2030 (USD MILLION) 273
TABLE 277 MEXICO: BIOCHIPS MARKET, BY END USER, 2023–2030 (USD MILLION) 274
TABLE 278 REST OF LATIN AMERICA: BIOCHIPS MARKET, BY PRODUCT & SERVICE,
2023–2030 (USD MILLION) 275
TABLE 279 REST OF LATIN AMERICA: BIOCHIPS MARKET, BY TYPE,
2023–2030 (USD MILLION) 275
TABLE 280 REST OF LATIN AMERICA: DNA CHIPS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 276
TABLE 281 REST OF LATIN AMERICA: LAB-ON-A-CHIP MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 276
TABLE 282 REST OF LATIN AMERICA: PROTEIN CHIPS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 277
TABLE 283 REST OF LATIN AMERICA: BIOCHIPS MARKET, BY FABRICATION TECHNOLOGY, 2023–2030 (USD MILLION) 277
TABLE 284 REST OF LATIN AMERICA: BIOCHIPS MARKET, BY END USER,
2023–2030 (USD MILLION) 278
TABLE 285 MIDDLE EAST & AFRICA: VOLUME ANALYSIS, BY TYPE,
2023–2030 (THOUSAND UNITS) 279
TABLE 286 MIDDLE EAST & AFRICA: BIOCHIPS MARKET, BY REGION,
2023–2030 (USD MILLION) 279
TABLE 287 MIDDLE EAST & AFRICA: BIOCHIPS MARKET, BY PRODUCT & SERVICE,
2023–2030 (USD MILLION) 279
TABLE 288 MIDDLE EAST & AFRICA: BIOCHIPS MARKET, BY TYPE, 2023–2030 (USD MILLION) 280
TABLE 289 MIDDLE EAST & AFRICA: DNA CHIPS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 280
TABLE 290 MIDDLE EAST & AFRICA: LAB-ON-A-CHIP MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 281
TABLE 291 MIDDLE EAST & AFRICA: PROTEIN CHIPS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 281
TABLE 292 MIDDLE EAST & AFRICA: BIOCHIPS MARKET, BY FABRICATION TECHNOLOGY, 2023–2030 (USD MILLION) 281
TABLE 293 MIDDLE EAST & AFRICA: BIOCHIPS MARKET, BY END USER,
2023–2030 (USD MILLION) 282
TABLE 294 GCC COUNTRIES: BIOCHIPS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 282
TABLE 295 GCC COUNTRIES: BIOCHIPS MARKET, BY PRODUCT & SERVICE,
2023–2030 (USD MILLION) 283
TABLE 296 GCC COUNTRIES: BIOCHIPS MARKET, BY TYPE, 2023–2030 (USD MILLION) 283
TABLE 297 GCC COUNTRIES: DNA CHIPS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 283
TABLE 298 GCC COUNTRIES: LAB-ON-A-CHIP MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 284
TABLE 299 GCC COUNTRIES: PROTEIN CHIPS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 284
TABLE 300 GCC COUNTRIES: BIOCHIPS MARKET, BY FABRICATION TECHNOLOGY,
2023–2030 (USD MILLION) 284
TABLE 301 GCC COUNTRIES: BIOCHIPS MARKET, BY END USER, 2023–2030 (USD MILLION) 285
TABLE 302 KINGDOM OF SAUDI ARABIA (KSA): KEY MACROECONOMIC INDICATORS 285
TABLE 303 KINGDOM OF SAUDI ARABIA (KSA): BIOCHIPS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 286
TABLE 304 KINGDOM OF SAUDI ARABIA (KSA): BIOCHIPS MARKET, BY TYPE,
2023–2030 (USD MILLION) 286
TABLE 305 KINGDOM OF SAUDI ARABIA (KSA): DNA CHIPS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 287
TABLE 306 KINGDOM OF SAUDI ARABIA (KSA): LAB-ON-A-CHIP MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 287
TABLE 307 KINGDOM OF SAUDI ARABIA (KSA): PROTEIN CHIPS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 288
TABLE 308 KINGDOM OF SAUDI ARABIA (KSA): BIOCHIPS MARKET, BY FABRICATION TECHNOLOGY, 2023–2030 (USD MILLION) 288
TABLE 309 KINGDOM OF SAUDI ARABIA (KSA): BIOCHIPS MARKET, BY END USER,
2023–2030 (USD MILLION) 289
TABLE 310 UNITED ARAB EMIRATES (UAE): KEY MACROECONOMIC INDICATORS 290
TABLE 311 UNITED ARAB EMIRATES (UAE): BIOCHIPS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 290
TABLE 312 UNITED ARAB EMIRATES (UAE): BIOCHIPS MARKET, BY TYPE,
2023–2030 (USD MILLION) 290
TABLE 313 UNITED ARAB EMIRATES (UAE): DNA CHIPS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 291
TABLE 314 UNITED ARAB EMIRATES (UAE): LAB-ON-A-CHIP MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 291
TABLE 315 UNITED ARAB EMIRATES (UAE): PROTEIN CHIPS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 292
TABLE 316 UNITED ARAB EMIRATES (UAE): BIOCHIPS MARKET, BY FABRICATION TECHNOLOGY, 2023–2030 (USD MILLION) 292
TABLE 317 UNITED ARAB EMIRATES (UAE): BIOCHIPS MARKET, BY END USER,
2023–2030 (USD MILLION) 293
TABLE 318 REST OF GCC COUNTRIES: BIOCHIPS MARKET, BY PRODUCT & SERVICE,
2023–2030 (USD MILLION) 293
TABLE 319 REST OF GCC COUNTRIES: BIOCHIPS MARKET, BY TYPE,
2023–2030 (USD MILLION) 294
TABLE 320 REST OF GCC COUNTRIES: DNA CHIPS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 294
TABLE 321 REST OF GCC COUNTRIES: LAB-ON-A-CHIP MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 295
TABLE 322 REST OF GCC COUNTRIES: PROTEIN CHIPS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 295
TABLE 323 REST OF GCC COUNTRIES: BIOCHIPS MARKET, BY FABRICATION TECHNOLOGY, 2023–2030 (USD MILLION) 295
TABLE 324 REST OF GCC COUNTRIES: BIOCHIPS MARKET, BY END USER,
2023–2030 (USD MILLION) 296
TABLE 325 REST OF MIDDLE EAST & AFRICA: BIOCHIPS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 296
TABLE 326 REST OF MIDDLE EAST & AFRICA: BIOCHIPS MARKET, BY TYPE,
2023–2030 (USD MILLION) 297
TABLE 327 REST OF MIDDLE EAST & AFRICA: DNA CHIPS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 297
TABLE 328 REST OF MIDDLE EAST & AFRICA: LAB-ON-A-CHIP MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 298
TABLE 329 REST OF MIDDLE EAST & AFRICA: PROTEIN CHIPS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 298
TABLE 330 REST OF MIDDLE EAST & AFRICA: BIOCHIPS MARKET, BY FABRICATION TECHNOLOGY, 2023–2030 (USD MILLION) 299
TABLE 331 REST OF MIDDLE EAST & AFRICA: BIOCHIPS MARKET, BY END USER,
2023–2030 (USD MILLION) 299
TABLE 332 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN
BIOCHIPS MARKET, 2022–2024 300
TABLE 333 GLOBAL BIOCHIPS MARKET: DEGREE OF COMPETITION 304
TABLE 334 US BIOCHIPS MARKET: DEGREE OF COMPETITION 307
TABLE 335 BIOCHIPS MARKET: REGION FOOTPRINT 313
TABLE 336 BIOCHIPS MARKET: PRODUCT & SERVICE FOOTPRINT 314
TABLE 337 BIOCHIPS MARKET: TYPE FOOTPRINT 315
TABLE 338 BIOCHIPS MARKET: FABRICATION TECHNOLOGY FOOTPRINT 316
TABLE 339 BIOCHIPS MARKET: DETAILED LIST OF KEY STARTUPS/SMES 318
TABLE 340 BIOCHIPS MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES 319
TABLE 341 BIOCHIPS MARKET: PRODUCT/SERVICE LAUNCHES, ENHANCEMENTS, AND APPROVALS, JANUARY 2022−SEPTEMBER 2025 320
TABLE 342 BIOCHIPS MARKET: DEALS, JANUARY 2022−SEPTEMBER 2025 321
TABLE 343 BIOCHIPS MARKET: EXPANSIONS, JANUARY 2022−SEPTEMBER 2025 322
TABLE 344 BIOCHIPS MARKET: OTHERS, JANUARY 2022–SEPTEMBER 2025 323
TABLE 345 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW 324
TABLE 346 THERMO FISHER SCIENTIFIC INC.: PRODUCTS/SERVICES OFFERED 325
TABLE 347 THERMO FISHER SCIENTIFIC INC.: PRODUCT/SERVICE LAUNCHES, ENHANCEMENTS, AND APPROVALS, JANUARY 2022−SEPTEMBER 2025 327
TABLE 348 ILLUMINA, INC.: COMPANY OVERVIEW 329
TABLE 349 ILLUMINA, INC.: PRODUCTS/SERVICES OFFERED 330
TABLE 350 ILLUMINA, INC.: PRODUCT/SERVICE LAUNCHES, ENHANCEMENTS, AND APPROVALS, JANUARY 2022−SEPTEMBER 2025 332
TABLE 351 ILLUMINA, INC.: DEALS, JANUARY 2022–SEPTEMBER 2025 332
TABLE 352 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW 334
TABLE 353 AGILENT TECHNOLOGIES, INC.: PRODUCTS/SERVICES OFFERED 335
TABLE 354 AGILENT TECHNOLOGIES, INC.: DEALS, JANUARY 2022–SEPTEMBER 2025 337
TABLE 355 AGILENT TECHNOLOGIES, INC.: EXPANSIONS, JANUARY 2022–SEPTEMBER 2025 337
TABLE 356 AGILENT TECHNOLOGIES, INC.: OTHER DEVELOPMENTS, JANUARY 2022−SEPTEMBER 2025 338
TABLE 357 F. HOFFMANN-LA ROCHE LTD: COMPANY OVERVIEW 340
TABLE 358 F. HOFFMANN-LA ROCHE LTD: PRODUCTS/SERVICES OFFERED 341
TABLE 359 F. HOFFMANN-LA ROCHE LTD: PRODUCT/SERVICE LAUNCHES, ENHANCEMENTS, AND APPROVALS, JANUARY 2022−SEPTEMBER 2025 342
TABLE 360 QIAGEN: COMPANY OVERVIEW 345
TABLE 361 QIAGEN: PRODUCTS/SERVICES OFFERED 346
TABLE 362 QIAGEN: PRODUCT/SERVICE LAUNCHES, ENHANCEMENTS, AND APPROVALS, JANUARY 2022−SEPTEMBER 2025 347
TABLE 363 QIAGEN: DEALS, JANUARY 2022–SEPTEMBER 2025 349
TABLE 364 QIAGEN: EXPANSIONS, JANUARY 2022–SEPTEMBER 2025 349
TABLE 365 QIAGEN: OTHER DEVELOPMENTS, JANUARY 2022−SEPTEMBER 2025 350
TABLE 366 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW 352
TABLE 367 BIO-RAD LABORATORIES, INC.: PRODUCTS/SERVICES OFFERED 353
TABLE 368 ABBOTT: COMPANY OVERVIEW 354
TABLE 369 ABBOTT: PRODUCTS/SERVICES OFFERED 355
TABLE 370 ABBOTT: PRODUCT/SERVICE LAUNCHES, ENHANCEMENTS, AND APPROVALS, JANUARY 2022−SEPTEMBER 2025 356
TABLE 371 STANDARD BIOTOOLS: COMPANY OVERVIEW 357
TABLE 372 STANDARD BIOTOOLS: PRODUCTS/SERVICES OFFERED 358
TABLE 373 STANDARD BIOTOOLS: PRODUCT/SERVICE LAUNCHES, ENHANCEMENTS, AND APPROVALS, JANUARY 2022−SEPTEMBER 2025 360
TABLE 374 STANDARD BIOTOOLS INC.: DEALS, JANUARY 2022−SEPTEMBER 2025 360
TABLE 375 STANDARD BIOTOOLS INC.: OTHER DEVELOPMENTS,
JANUARY 2022−SEPTEMBER 2025 361
TABLE 376 10X GENOMICS: COMPANY OVERVIEW 362
TABLE 377 10X GENOMICS: PRODUCTS/SERVICES OFFERED 363
TABLE 378 10X GENOMICS: PRODUCT/SERVICE LAUNCHES, ENHANCEMENTS, AND APPROVALS, JANUARY 2022−SEPTEMBER 2025 365
TABLE 379 10X GENOMICS: DEALS, JANUARY 2022−SEPTEMBER 2025 366
TABLE 380 10X GENOMICS: OTHER DEVELOPMENTS, JANUARY 2022−SEPTEMBER 2025 367
TABLE 381 CEPHEID: COMPANY OVERVIEW 368
TABLE 382 CEPHEID: PRODUCTS/SERVICES OFFERED 368
TABLE 383 CEPHEID: PRODUCT/SERVICE LAUNCHES, ENHANCEMENTS, AND APPROVALS, JANUARY 2022−SEPTEMBER 2025 370
TABLE 384 CEPHEID: DEALS, JANUARY 2022−SEPTEMBER 2025 372
TABLE 385 CEPHEID: OTHER DEVELOPMENTS, JANUARY 2022−SEPTEMBER 2025 373
TABLE 386 BIOMÉRIEUX: COMPANY OVERVIEW 374
TABLE 387 BIOMÉRIEUX: PRODUCTS/SERVICES OFFERED 375
TABLE 388 BIOMÉRIEUX: PRODUCT/SERVICE LAUNCHES, ENHANCEMENTS, AND APPROVALS, JANUARY 2022−SEPTEMBER 2025 376
TABLE 389 BIOMÉRIEUX: DEALS, JANUARY 2022–SEPTEMBER 2025 377
TABLE 390 REVVITY: COMPANY OVERVIEW 378
TABLE 391 REVVITY: PRODUCTS/SERVICES OFFERED 380
TABLE 392 REVVITY: DEALS, JANUARY 2022−SEPTEMBER 2025 382
TABLE 393 DIASORIN S.P.A.: COMPANY OVERVIEW 383
TABLE 394 DIASORIN S.P.A.: PRODUCTS/SERVICES OFFERED 384
TABLE 395 RANDOX LABORATORIES LTD.: COMPANY OVERVIEW 386
TABLE 396 RANDOX LABORATORIES LTD.: PRODUCTS/SERVICES OFFERED 386
TABLE 397 RANDOX LABORATORIES LTD.: PRODUCT/SERVICE LAUNCHES, ENHANCEMENTS, AND APPROVALS, JANUARY 2022−SEPTEMBER 2025 388
TABLE 398 RANDOX LABORATORIES LTD.: DEALS, JANUARY 2022−SEPTEMBER 2025 388
TABLE 399 RANDOX LABORATORIES LTD.: EXPANSIONS, JANUARY 2022–SEPTEMBER 2025 389
TABLE 400 OXFORD GENE TECHNOLOGY IP LIMITED: COMPANY OVERVIEW 390
TABLE 401 OXFORD GENE TECHNOLOGY IP LIMITED: PRODUCTS/SERVICES OFFERED 390
TABLE 402 MICRONIT B.V.: COMPANY OVERVIEW 392
TABLE 403 RAYBIOTECH, INC.: COMPANY OVERVIEW 393
TABLE 404 PHALANX BIOTECH GROUP: COMPANY OVERVIEW 394
TABLE 405 ARRAYIT CORPORATION: COMPANY OVERVIEW 395
TABLE 406 3DHISTECH LTD.: COMPANY OVERVIEW 396
TABLE 407 CREATIVE BIOARRAY: COMPANY OVERVIEW 397
TABLE 408 TISSUEARRAY.COM: COMPANY OVERVIEW 399
TABLE 409 IBIOCHIPS: COMPANY OVERVIEW 400
TABLE 410 CAPITALBIOTECH CO., LTD.: COMPANY OVERVIEW 401
TABLE 411 PEPPERPRINT GMBH: COMPANY OVERVIEW 402
LIST OF FIGURES
FIGURE 1 BIOCHIPS MARKET SEGMENTATION AND REGIONAL SCOPE 32
FIGURE 2 BIOCHIPS MARKET: RESEARCH DESIGN 37
FIGURE 3 PRIMARY SOURCES 39
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE,
DESIGNATION, AND REGION (SUPPLY SIDE) 41
FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: BY END USER,
DESIGNATION, AND REGION (DEMAND SIDE) 42
FIGURE 6 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS 42
FIGURE 7 SUPPLY-SIDE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS 43
FIGURE 8 REVENUE SHARE ANALYSIS ILLUSTRATION: THERMO FISHER SCIENTIFIC INC. 44
FIGURE 9 REVENUE ANALYSIS OF TOP FIVE COMPANIES: BIOCHIPS MARKET (2024) 44
FIGURE 10 DEMAND-SIDE MARKET ESTIMATION FOR BIOCHIPS 46
FIGURE 11 CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF BIOCHIPS MARKET (2025–2030) 47
FIGURE 12 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 47
FIGURE 13 TOP-DOWN APPROACH 48
FIGURE 14 BOTTOM-UP APPROACH 49
FIGURE 15 MARKET DATA TRIANGULATION METHODOLOGY 50
FIGURE 16 BIOCHIPS MARKET, BY PRODUCTS & SERVICES, 2025 VS. 2030 (USD MILLION) 53
FIGURE 17 BIOCHIPS MARKET, BY TYPE, 2025 VS. 2030 (USD MILLION) 54
FIGURE 18 DNA CHIPS MARKET, BY APPLICATION, 2025 VS. 2030 (USD MILLION) 54
FIGURE 19 LAB-ON-A-CHIP MARKET, BY APPLICATION, 2025 VS. 2030 (USD MILLION) 55
FIGURE 20 PROTEIN CHIPS MARKET, BY APPLICATION, 2025 VS. 2030 (USD MILLION) 55
FIGURE 21 BIOCHIPS MARKET, BY FABRICATION TECHNOLOGY,
2025 VS. 2030 (USD MILLION) 56
FIGURE 22 BIOCHIPS MARKET, BY END USER, 2025 VS. 2030 (USD MILLION) 56
FIGURE 23 GEOGRAPHIC SNAPSHOT OF BIOCHIPS MARKET 57
FIGURE 24 INCREASING INCIDENCE OF CHRONIC CONDITIONS TO FUEL MARKET 58
FIGURE 25 CONSUMABLES SEGMENT AND CHINA LED ASIA PACIFIC MARKET IN 2024 59
FIGURE 26 ASIA PACIFIC REGION TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD 60
FIGURE 27 CHINA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD 60
FIGURE 28 EMERGING ECONOMIES TO REGISTER HIGHER GROWTH RATES DURING FORECAST PERIOD 61
FIGURE 29 BIOCHIPS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 62
FIGURE 30 BIOCHIPS MARKET: PORTER’S FIVE FORCES ANALYSIS 76
FIGURE 31 BIOCHIPS MARKET: PATENT ANALYSIS, JANUARY 2014–OCTOBER 2025 82
FIGURE 32 TOP APPLICANTS FOR BIOCHIPS PATENTS, BY JURISDICTION,
JANUARY 2014–OCTOBER 2025 83
FIGURE 33 AVERAGE SELLING PRICE FOR DNA CHIPS AND LAB-ON-A-CHIP,
BY KEY PLAYER, 2024 87
FIGURE 34 AVERAGE SELLING PRICE FOR DNA CHIPS AND LAB-ON-A-CHIP, BY REGION, 2024 88
FIGURE 35 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR BIOCHIPS,
BY PRODUCT 90
FIGURE 36 KEY BUYING CRITERIA FOR TOP THREE END USERS 92
FIGURE 37 AI-USE CASES 94
FIGURE 38 BIOCHIPS MARKET: ECOSYSTEM MARKET MAP 96
FIGURE 39 BIOCHIPS MARKET: VALUE CHAIN ANALYSIS 99
FIGURE 40 BIOCHIPS MARKET: SUPPLY CHAIN ANALYSIS 101
FIGURE 41 REVENUE SHIFT AND NEW REVENUE POCKETS FOR BIOCHIPS MARKET 101
FIGURE 42 BIOCHIPS MARKET: GEOGRAPHIC SNAPSHOT 189
FIGURE 43 NORTH AMERICA: BIOCHIPS MARKET SNAPSHOT 191
FIGURE 44 ASIA PACIFIC: BIOCHIPS MARKET SNAPSHOT 233
FIGURE 45 REVENUE ANALYSIS OF KEY PLAYERS IN BIOCHIPS MARKET, 2020−2024 303
FIGURE 46 MARKET SHARE ANALYSIS OF KEY PLAYERS IN BIOCHIPS MARKET, 2024 304
FIGURE 47 RANKING OF KEY PLAYERS IN BIOCHIPS MARKET, 2024 305
FIGURE 48 US: MARKET SHARE ANALYSIS OF KEY PLAYERS IN BIOCHIPS MARKET, 2024 306
FIGURE 49 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK
BETA OF KEY VENDORS 307
FIGURE 50 EV/EBITDA OF KEY VENDORS 308
FIGURE 51 BIOCHIPS MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS 309
FIGURE 52 R&D EXPENDITURE OF KEY PLAYERS IN BIOCHIPS MARKET, 2022−2024 310
FIGURE 53 BIOCHIPS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024 311
FIGURE 54 BIOCHIPS MARKET: COMPANY FOOTPRINT 312
FIGURE 55 BIOCHIPS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024 317
FIGURE 56 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2024) 325
FIGURE 57 ILLUMINA, INC.: COMPANY SNAPSHOT (2024) 330
FIGURE 58 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2024) 335
FIGURE 59 F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT (2024) 341
FIGURE 60 QIAGEN: COMPANY SNAPSHOT (2024) 346
FIGURE 61 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2024) 353
FIGURE 62 ABBOTT: COMPANY SNAPSHOT (2024) 355
FIGURE 63 STANDARD BIOTOOLS: COMPANY SNAPSHOT (2024) 358
FIGURE 64 10X GENOMICS: COMPANY SNAPSHOT (2024) 363
FIGURE 65 BIOMÉRIEUX: COMPANY SNAPSHOT (2024) 375
FIGURE 66 REVVITY: COMPANY SNAPSHOT (2024) 379
FIGURE 67 DIASORIN S.P.A.: COMPANY SNAPSHOT (2024) 384
MarketsandMarkets（マーケッツアンドマーケッツ）は世界中の企業に高い評価を得ており、著名メディアでの引用頻度も高い、インドの最大手級の市場調査会社です。広範な市場を対象にした市場調査レポートを出版しています。
※MarketsandMarketsの調査レポートはほぼ全タイトルご注文後、最短3時間～12時間以内（営業日基準）にご納品可能です。
ライセンス別価格表
調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。
ライセンスタイプ1
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD4,950 | USD6,650 | USD8,150 | USD10,000 |
ライセンスタイプ2
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD7,150 | USD8,500 | USD9,650 | USD11,000 |
ライセンスタイプ3
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD8,150 | お問合せください | お問合せください | お問合せください |
ライセンスタイプ4
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD9,000 | USD10,500 | USD12,000 | USD13,500 |
ミニレポート ※定性調査にフォーカスした調査レポートです。詳細はお問合せください。
| シングルユーザ | コーポレート |
| USD 2,650 | USD 4,250 |
ご購入に関するご案内
価格・納期について
- 価格
- ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
- ライセンス
- シングルユーザライセンス
- 1名のみレポートファイルのご利用が可能です。
- マルチユーザライセンス
- 同一企業内（関連会社除く）5名までレポートファイルのご利用が可能です。
- コーポレートライセンス
- 同一企業および100％持株会社間・人数無制限でレポートファイルのご利用が可能です。
- エンタープライズサイトライセンス
- 特別ライセンスです。適用範囲についてはお問合せください。
- シングルユーザライセンス
- 納品形態
- Eメール
- 納期
- 最短3時間以内にご納品可能です。通常ご注文後24時間以内（営業日基準）
ご注文方法
- レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。
その他
- 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。
株式会社SEMABIZはMarketsandMarketsの日本に拠点をおく販売代理店として、MarketsandMarketsのレポートを販売しております。サンプルページのご依頼、見積り、レポートに関するご質問など購入前のご相談はいつでもお気軽にご連絡ください。
最新調査レポート
- 自動車用アラミド繊維市場規模、シェア、動向、2030年までの世界予測 2025-12-15
- ポリヒドロキシアルカノエート (PHA) 市場規模、シェア、動向、2030年までの世界予測 2025-12-15
- 複合輸送市場規模、シェア、動向、2032年までの世界予測 2025-12-12
- ハイブリッドボンディング市場規模、シェア、動向、2032年までの世界予測 2025-12-11
- 鉄道試験市場規模、シェア、動向、2032年までの世界予測 2025-12-10